搜狐

新生儿致命代谢紊乱MoCD A型治疗取得成功

药物fosdenopterin/rcPMP显著提高了患有钼辅因子缺乏（MoCD A型）新生儿的生存几率和发育进展。近日，科隆大学生物化学研究所的 ...
搜狐

香港迈极康 | Nulibry(fosdenopterin)治疗A型MoCD在欧盟获上市许可

2022年9月22日讯 / 香港迈极康hkmagicure / -- BridgeBio Pharma,Inc.和Sentynl Therapeutics,Inc.于9月20日联合宣布，欧盟委员会(EC)已授予Nulibry(fosdenopterin)注射液上市许可，作为治疗A型钼辅因子缺乏症(MoCD)患者的 ...
Science Daily

Successful therapy confirmed for newborns with the fatal metabolic disorder MoCD type A

Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
technologynetworks

Therapy for Newborns With MoCD Type A Shows Promising Clinical Trial Results

The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a ...
生物谷

罕见病底物替代疗法！美国FDA授予fosdenopterin优先审查：治疗A型钼辅因子缺乏症（MoCD）！

目前，尚无治疗A型MoCD的药物获得批准。 2020年09月30日讯 /生物谷BIOON/ --BridgeBio制药公司及其子公司Origin Biosciences近日宣布 ...
헬스코리아뉴스

전세계 환자 150명 미만 … MoCD 치료제 ‘널리브리’ 美 이어 유럽서도 승인

[헬스코리아뉴스/ 이충만] 전세계적으로 150명 미만의 환자들만이 있는 것으로 알려진 희귀질환 몰리브덴 조효소 결핍증(MoCD)에 대한 최초의 치료제가 미국에 이어 유럽에서도 사용 가능해졌다.
Yahoo Finance

BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Indiatimes

Zydus’ US arm gets EC authorisation for MoCD injection

AHMEDABAD: Homegrown pharma major, Zydus Lifesciences Limited’s wholly-owned subsidiary, US-based Sentynl Therapeutics, along with BridgeBio Pharma received a marketing authorisation from the European ...